PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis

被引:98
作者
Ding, HL
Wu, XF [1 ]
Gao, W
机构
[1] Third Mil Med Univ, Dept Nephrol, Southwest Hosp, Chongqing 400038, Peoples R China
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Immunol,Transplant Res Ctr, Boston, MA 02215 USA
基金
中国国家自然科学基金;
关键词
renal tubular epithelial cells; PD-L1; T cells; cytokine;
D O I
10.1016/j.clim.2005.01.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
T cell activation is affected by both stimulatory and inhibitory co-signaling. NIHC class II-expressing renal tubular epithelial cells (TEC) can function as APC for T cells. To study the influence of inhibitory ligands oil TEC-mediated T cell activation, we examined the expression of programmed death ligand-1 (PD-L1) on human TEC line HK-2 cells, as well as in normal and diseased kidney samples. RT-PCR, FACS, and immunocytochemistry showed that PD-L1 is constitutively expressed on HK-2 cells, and is dramatically Upregulated by IFN-gamma. In situ hybridization and immunohistochemical staining revealed constitutive low expression of PD-L1 on proximal tubules at both mRNA and protein levels in normal kidneys, but much higher expression in kidneys with type IV lupus nephritis. In vitro, pretreatment of IFN-gamma-stimulated HK-2 cells with anti-PD-L1 significantly enhanced IL-2 secretion from cocultured, mitogen-activated Jurkat or human peripheral blood T cells. These results suggest that the PD-L1:PD-1 pathway negatively regulates T cell activation by TEC, and may play an inhibitory role in TEC-mediated immune activation and immunopathology in the kidney. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:184 / 191
页数:8
相关论文
共 64 条
[1]   Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].
Agata, Y ;
Kawasaki, A ;
Nishimura, H ;
Ishida, Y ;
Tsubata, T ;
Yagita, H ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772
[2]   The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice [J].
Ansari, MJI ;
Salama, AD ;
Chitnis, T ;
Smith, RN ;
Yagita, H ;
Akiba, H ;
Yamazaki, T ;
Azuma, M ;
Iwai, H ;
Khoury, SJ ;
Auchincloss, H ;
Sayegh, MH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (01) :63-69
[3]   THE CD40 ANTIGEN AND ITS LIGAND [J].
BANCHEREAU, J ;
BAZAN, F ;
BLANCHARD, D ;
BRIERE, F ;
GALIZZI, JP ;
VANKOOTEN, C ;
LIU, YJ ;
ROUSSET, F ;
SAELAND, S .
ANNUAL REVIEW OF IMMUNOLOGY, 1994, 12 :881-922
[4]   PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].
Blank, C ;
Brown, I ;
Peterson, AC ;
Spiotto, M ;
Iwai, Y ;
Honjo, T ;
Gajewski, TF .
CANCER RESEARCH, 2004, 64 (03) :1140-1145
[5]   Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism [J].
Blazar, BR ;
Carreno, BM ;
Panoskaltsis-Mortari, A ;
Carter, L ;
Iwai, Y ;
Yagita, H ;
Nishimura, H ;
Taylor, PA .
JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1272-1277
[6]   Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production [J].
Brown, JA ;
Dorfman, DM ;
Ma, FR ;
Sullivan, EL ;
Munoz, O ;
Wood, CR ;
Greenfield, EA ;
Freeman, GJ .
JOURNAL OF IMMUNOLOGY, 2003, 170 (03) :1257-1266
[7]  
Carter LL, 2002, EUR J IMMUNOL, V32, P634, DOI 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO
[8]  
2-9
[9]   SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation [J].
Chemnitz, JM ;
Parry, RV ;
Nichols, KE ;
June, CH ;
Riley, JL .
JOURNAL OF IMMUNOLOGY, 2004, 173 (02) :945-954
[10]   Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity [J].
Chen, LP .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (05) :336-347